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Abstract
Spinal muscular atrophy (SMA) is caused by loss of the Survival Motor Neuron 1 (SMN1) gene, resulting in reduced SMN
protein. Humans possess the additional SMN2 gene (or genes) that does produce low level of full length SMN, but cannot
adequately compensate for loss of SMN1 due to aberrant splicing. The majority of SMN2 gene transcripts lack exon 7 and
the resultant SMND7 mRNA is translated into an unstable and non-functional protein. Splice intervention therapies to
promote exon 7 retention and increase amounts of full-length SMN2 transcript offer great potential as a treatment for SMA
patients. Several splice silencing motifs in SMN2 have been identified as potential targets for antisense oligonucleotide
mediated splice modification. A strong splice silencer is located downstream of exon 7 in SMN2 intron 7. Antisense
oligonucleotides targeting this motif promoted SMN2 exon 7 retention in the mature SMN2 transcripts, with increased SMN
expression detected in SMA fibroblasts. We report here systematic optimisation of phosphorodiamidate morpholino
oligonucleotides (PMO) that promote exon 7 retention to levels that rescued the phenotype in a severe mouse model of
SMA after intracerebroventricular delivery. Furthermore, the PMO gives the longest survival reported to date after a single
dosing by ICV.
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Introduction
Spinal muscular atrophy (SMA), the second most common
autosomal recessive disorder in Caucasians, is the leading genetic
cause of death in children under the age of 2 years [1]. Three
forms of SMA are classified by the severity of the clinical
presentation, with type I SMA being the most severe, and type III
SMA the mildest. SMA is caused most commonly by loss of the
SMN1 gene, resulting in substantial reductions in levels of
functional SMN protein. SMN2, which is retained in SMA,
cannot adequately compensate for SMN1 loss unless present at
high copy number [2,3]. The reason being that the majority of
SMN2 transcripts are inappropriately processed and lack exon 7
(SMND7) [4]. The SMND7 mRNA is translated into a truncated
protein, which is incapable of self-association and leads to the
production of a highly unstable SMN protein [5,6]. Gene
replacement therapy for SMN protein is one of the most direct
approaches to treat SMA patients, however the delivery issue has
long been an obstacle, because the blood brain barrier (BBB)
restricts delivery of therapeutics to the central nervous system
(CNS), where an insufficiency of functional SMN has the most
severe consequences [7,8,9]. Subsequently, four groups have now
produced scAAV9-SMN and reported a remarkable correction of
the SMA phenotype with the highest titer virus resulting in mice
surviving over 400 days [10,11,12,13]. These studies demonstrated
that replacement of SMN, at least early, is an effective therapy;
however certainly difficulties remain in terms of sufficient vector
production particularly if applied to older SMA patients. In-
terestingly, the scAAV9 does cross the BBB even in older animals
in monkeys and can also give efficient transduction of motor
neurons when introduced intrathecally, which reduces the amount
of virus required [14].
An alternative approach to treat SMA is the application of
antisense oligonucleotides to promote SMN2 exon 7 retention.
Relatively low expression of full-length SMN from SMN2 arises
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from a C.T change in exon 7 that disrupts an exonic splice
enhancer (SF2/ASF), with the concomitant creation of an exonic
silencer element [15,16]. This leads to suppression of exon 7
recognition and thus reduced incorporation of this exon in mature
SMN2 mRNA [4]. Critical intronic silencing motifs have been
identified in introns 6 and 7 [17,18,19], the intronic silencing motif
(ISS-N1) was identified as the most responsive target for the AO
induced splice modification strategy [18,20,21].
This work describes further refinement and optimisation of
phosphorodiamidate morpholino oligonucleotides (PMOs) target-
ing ISS-N1. A panel of 14 PMO of varying lengths was designed to
anneal downstream of SMN2 exon 7, encompassing the ISS-N1
region. Efficiency was studied in vitro in cultured fibroblasts from
a type I SMA patient, and subsequently confirmed in vivo after the
lead compound in a one timing dosing rescued a severely affected
mouse model after intracerebroventricular (ICV) administration.
Results
Refining Oligonucleotide Design to Enhance SMN2 Exon
7 Incorporation
Efficiency of AO to promote FL-SMN can be enhanced by
increasing the oligonucleotide length. Fourteen different PMOs
varying in size of 20, 22 and 25 mers were designed to anneal to or
near ISS-N1 (-10-25) (Table 1 and Figure S1) and were
transfected into fibroblasts derived from an SMA Type I patient
using PMO:Leash with lipofection delivery system (Figure 1,
Figure 2, Figure 3, Figure 4, Figure 5).
Of the five PMO20mers that annealed between intronic bases 8
to 35 downstream of exon 7, PMO(-10-29) was the most efficient
at inducing the full length SMN2 transcript retaining exon 7
(Figure 1). Extending the length of PMO(-10-29) by five bases at
the 5’ end, PMO(-10-34), further improved the efficiency of exon
inclusion in SMN2, clearly evident in a clear dose-dependant
response. In contrast, extending PMO length by 5 bases at the 3’
end, PMO(-5-29) resulted in diminished SMN2 exon 7 inclusion
level. Similarly, PMO25mers that targeted intron 7 regions further
downstream of ISS-N1 (-14-38) also lost the ability to promote
exon 7 retention in the SMN2 transcripts (Figure 2). Further
indication of the narrow window for PMO targeting to re-inforce
SMN2 exon 7 recognition and retention was seen after in-
terrogating the area with a panel of PMO 22mers. PMO(-10-31)
generated a clear dose dependant of exon 7 retention, whereas
PMO(-12-33) was essentially inactive, as were other PMO22mers
(PMO(-14-35) and PMO(-16-37)) (Figure 3).
In vitro Titration Studies and Western Blotting
Titration studies of the three lead PMO candidates (20, 22, and
25mers) were undertaken to demonstrate dose responses, and
identify the lead compound for further pre-clinical animal
evaluation. Densitometric analysis of RT-PCR results showed
that SMN exon 7 inclusion was induced by PMO(-10-34) at the
concentration of 37.5 nM, while the 20 and 22mers PMOs were
active only when transfected at higher concentrations (150 or
75 nM) in a type I SMA fibroblast (Figure 4).
Western blotting confirmed enhanced induction of the SMN
protein in SMA type I fibroblasts. Transfection of SMA fibroblasts
with PMO(-10-29) and PMO(-10-31) induced 1.86 and 1.83 fold
increases in SMN protein at the concentration of 600 nM, while
PMO(-10-34) treatment led to a 2.49 fold increase, when
compared to the average of sham PMO treatment at equivalent
concentrations and untreated SMA fibroblasts. At a transfection
concentration of 300 nM, the fold change of induced SMN
protein in SMA fibroblasts transfected with PMO(-10-29), PMO(-
10-31) or PMO(-10-34) was 1.47, 1.83 and 2.00 fold, respectively
(Figure 5).
Subsequently, we utilised the second PMO delivery system to
confirm the effect of selected PMO on the enhanced level of SMN
protein expression in SMA fibroblast (Figure 6). Nucleofection
was also evaluated to compare efficiency of PMO candidates. The
level of induced SMN protein from SMA patient derived
fibroblasts after nucleofection with PMO(-10-34) was higher than
those of SMA fibroblasts treated with either PMO(-10-29) or
PMO(-10-31) (Figure 6). Taken together, PMO(-10-34) was
identified as the most effective compound for induction of SMN
protein after two different in vitro delivery systems and this
oligonucleotide was selected for further in vivo evaluation.
PMO(-10-34) Increased Expression of SMN Protein in SMA
Carrier Mice
To study the effect of PMO on enhanced expression of SMN
in vivo, SMA carrier mice (genotype Smn+/2; SMN2+/+; D7+/+)
were used. PMO(-10-34) and scrambled PMO were intracereb-
roventricularly injected into SMA carrier mice. Human specific
SMN antibody (KH antibody) was used for immunodetection to
visualise enhanced human SMN protein expression. Substantially
increased SMN protein expression in both spinal cord and brain
was noted in 21 and 65 days after 6 mM injection of PMO(-10-34)
(Figure 7a and b).
PMO(-10-34) Extended Survival of a Severe Mouse Model
of SMA
Three different PMOs, PMO(-10-34), PMO(-10-29) and
scrambled PMO were intracerebroventricularly administered into
SMA mice (genotype mSmn 2/2; SMN2+/+; D7+/+), at doses
indicated. The survival curve of SMA mice injected with a single
ICV dose of PMO(-10-34) significantly prolonged survival of SMA
mice at all doses (Figure 8 and Table 2). Median survival
increased from 15 days (untreated SMA animal, scrambled PMO
injection) to a median range of 37 to 126 days for the five dosing
strategies. Among SMA mice treated with five different doses of
PMO(-10-34), pairwise analysis indicated that the median survival
of SMA mice injected with 0.5 mM was significantly different
from those mice treated with either 2, 4 or 6 mM. In keeping with
the trend of the survival, the weight of mice injected with PMO(-
10-34) at 4 or 6 mM was higher than that of mice injected with
either 0.5, 1 or 2 mM of PMO(-10-34) (Figure 9).
Median survival of SMA mice injected with PMO(-10-34) and
PMO(-10-29) at dosages of 2, 4 and 6 mM were compared, and
the median survival time of PMO(-10-34) treatment group was
higher than that of mice treated with PMO(-10-29) at all three
doses (Table 3). However, these differences were not statistically
significant (P-value 0.084 for median survival time, P-value 0.097
for Log Rank test for survival curve).
Discussion
We previously reported that increasing oligonucleotide length
could enhance the efficiency of some compounds, at least when
targeting some exons in the dystrophin gene transcript [22]. We
have employed a similar strategy to optimise SMN2 pre-mRNA
processing with a systematic refinement of oligonucleotide design.
The initial microwalk was undertaken by using five 20mer PMOs,
which annealed to the intron 7 between intronic bases 8 to 35 base
downstream from exon 7, and only PMO(-10-29) and PMO(-8-27)
increased levels of full-length SMN (FL-SMN) transcript above
that observed in untreated cells. PMOs extended by 5 bases at
either end of PMO(-10-29) were evaluated, and the 25mer PMO
AO Design to Suppress Aberrant SMN2 Splicing
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(PMO(-10-34)) was found to be most effective in promoting exon 7
inclusion. This was most evident after in vitro transfection into
SMA patient fibroblasts at the lower concentrations, while 22-mer
PMO (PMO(-10-31)) induced less pronounced levels of the FL-
SMN transcript.
We have previously shown that subtle changes in oligonucle-
otide design can significantly influence the efficiency of AO, with
respect to exon skipping in the dystrophin gene [23,24], and this
study confirms that minor changes in oligonucleotide sequences
can be most significant when targeting splice silencers. PMO(-11-
35), displaced by only one base further into the intron than PMO(-
10-34), showed almost no SMN exon 7 inclusion activity after
transfection of PMO:leash lipoplexes at the concentrations of 75
and 37.5 nM. Four overlapping PMO22mers were designed and
evaluated to further refine optimal coordinates to promote the FL-
SMN transcript. PMO(-10-31) also induced pronounced exon 7
inclusion, but once again a narrow window of oligonucleotide
targeting was observed. This finding was in keeping with the
evolutionary significance of the ISS-N1 motif in humans, as mouse
Smn gene does not contain the first few bases of ISS-N1 motif
[19].
Titration studies were undertaken to rank SMN2 exon 7
retention efficiency of PMO(-10-29), PMO(-10-31) and PMO(-10-
34) in type I SMA fibroblasts. PMO(-10-34) induced inclusion of
Figure 1. a) Splicing pattern of SMN transcripts in type I SMA patient cells transfected with a panel of 20-mer PMOs, unrelated
negative control (Sham PMO) using lipofectin or untransfected fibroblasts (Untreated). b) The lower panel shows the average of
percentage of SMN2 exon 7 inclusion, as determined by densitometric analysis of RT-PCR gel images.
doi:10.1371/journal.pone.0062114.g001
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SMN exon 7 at all concentrations evaluated, while PMO(-10-29)
and PMO(-10-31) only increased FL-SMN transcript levels after
transfection at two highest tested concentrations (150 and 75 nM),
as assessed by RT-PCR assays. These PMOs were further
evaluated by comparing their efficiencies at inducing SMN
protein in type I SMA fibroblasts using different protocols (leash
and cationic lipoplex or nucleofection). PMO(-10-34) induced
substantial more SMN expression than the other two shorter
PMOs, based upon western blotting. The finding is in keeping
with another study to compare three oligonucleotides targeting
ISS-N1 [25].
Subsequently, PMO(-10-34) was assessed for its effect on
enhanced SMN protein expression in SMA carrier mice using
a human specific antibody. Robust expression of SMN protein
observed at day 21 and 65 after single ICV injection confirmed
our observation in vitro and this compound was chosen as the
lead candidate for further studies and evaluated in a severe
mouse model of SMA, allowing a direct comparison of our
previously reported PMO(-10-29) [21]. Untreated, the severely
affected pups normally succumb to the disease by postnatal day
15, and they can survive a median of 2–3 days longer, if
maternal diet contains higher fat content [26]. In line with our
earlier studies, a single ICV injection of PMO(-10-34) signifi-
cantly prolonged the lifespan of SMA mice, compared to sham
PMO, at all 5 tested doses.
Average survival of SMA mice injected with PMO(-10-34)
was not statistically significant between the three dose cohorts,
i.e. 2 mM, 4 mM and 6 mM, and was similar to that previously
reported on SMA mice injected with PMO(-10-29) [21]. SMA
mice were treated with lower dosages to identify minimum
thresholds for therapeutic doses. It was found that the survival
of the SMA mice, injected with PMO(-10-34) at 0.5 mM, was
significantly shorter than littermates injected with either 2 mM,
4 mM or 6 mM of PMO(-10-34). However, when considering
the mass of injected mice, we observed that mice injected with
either 4 mM or 6 mM of PMO(-10-34) gained substantially
more weight compared to that of mice injected with other lower
doses. We inferred that the therapeutic doses for SMA mice
should be 4–6 mM considering both survival and the weight
gain. This study demonstrated the optimal dose for single bolus
ICV injection; however a number of delivery methods; such as
continuous infusion through implantable intrathecal or in-
traventricular catheter or multi-dose bolus injection, are also
options for drug delivery in human. A study interrogating the
method of PMO delivery is required in particular a redosing
regime to determine whether further survival benefit can be
obtained. Indeed the comparison of ASO needs to consider
both the dose and frequency of redosing. When comparing
PMO(-10-29) to PMO(-10-34) the effective cost and redosing
regime are all critical in determining what moves forward for
clinical experimentation.
There were no obvious adverse effects on the SMA mice
injected with PMO(-10-34) in their first 50 days of life. However,
these mice displayed ear and tail necrosis, arising from day 50
through 90, similar to that observed in PMO(-10-29) treated SMA
mice [21]. Some PMO(-10-34) treated animals developed paw or
snout necrosis, but this was only observed in SMA mice that lived
generally more than 100 days. Some of the older survivors
developed bowel and bladder obstructions, and required manual
decompression and systemic antibiotics to alleviate the symptoms.
In addition to bladder and bowel obstruction, priapism and
peripheral necrosis were also observed in the longer lived SMA
mice, and these findings were what previously observed in rescued
SMA mice [21,27]. One key in the future is whether redosing the
ASO in an effective manner so it alters SMN2 splicing distal to the
inoculation site reduces or eliminates these issues. The digital
necrosis was also previously reported in two patients with type I
SMA who received proactive nutritional and respiratory care and
therefore lived longer [28]. These morbidities could represent
dysfunction of the autonomic nervous system (ANS), which is
partially located outside the central nervous system. Hua et al.
demonstrated that additional delivery of oligonucleotide either by
ICV injection at postnatal day 1 or by subcutaneous injection at
postnatal day 5 or 7 can delay necrosis [29]. However the overall
dose of the oligonucleotide was higher and at the early stage of
mouse development (P0–P7) the blood brain barrier is open to AO
treatment making it hard to determine whether this is due to
a peripheral or central targets. Taken together, re-administration
of PMO could rescue the peripheral necrosis and some or all of the
peripheral structure of ANS may perhaps need to be treated, as it
has also demonstrated using systemic administration of vivo-PMO,
which is more effective than PMO to target the SMN gene in the
periphery [25]. This study assessed the consequences of a single
administration of PMO, and Longer term survival with reduced
complications observed in SMA mice or type I SMA patients will
obviously require appropriate re-administration protocol to deliver
PMO. In this regard, it will be important to obtain adequate
distribution of the PMO in the CNS in both neonatal and adult
animals.
Comparative analysis of the two PMOs on the survival of SMA
mice indicated that PMO(-10-34) significantly extended the life-
span of treated SMA mice, and the effectiveness is dose responsive.
When comparing to PMO(-10-29), the survival of mice injected
with PMO(-10-34) is equal to, or higher than mice injected with
PMO(-10-29), even though the difference do not reach statistical
significance. However, the differences of the survival between two
treatment groups is more prominent at higher dose. The key
question will be the dosing and redosing scheme that is optimal for
long-term correction of SMA mice.
In summary, we have undertaken a systemic screening of
oligonucleotides targeting ISS-N1 and substantially enhanced
oligonucleotide design, so that the lead compound PMO(-10-34)
increased FL-transcript and SMN protein in vitro and prolong the
survival in vivo. While there was no statistical difference between
Table 1. The list of the 14 PMOs examined in this study.
Name Sequence (59–39) Size
SMN2E7D(-10-29) AUU CAC UUU CAU AAU GCU GG 20
SMN2E7D(-10-34) GUA AGA UUC ACU UUC AUA AUG CUG G 25
SMN2E7D(5-29) AUU CAC UUU CAU AAU GCU GGC AGA A 25
SMN2E7D(-10-31) AGA UUC ACU UUC AUA AUG CUG G 22
SMN2E7D(-12-33) UAA GAU UCA CUU UCA UAA UGC U 22
SMN2E7D(-14-35) AGU AAG AUU CAC UUU CAU AAU G 22
SMN2E7D(-16-37) AAA GUA AGA UUC ACU UUC AUA A 22
SMN2E7D(-8-27) UCA CUU UCA UAA UGC UGG CA 20
SMN2E7D(-12-31) AGA UUC ACU UUC AUA AUG CU 20
SMN2E7D(-14-33) UAA GAU UCA CUU UCA UAA UG 20
SMN2E7D(-16-35) AGU AAG AUU CAC UUU CAU AA 20
SMN2E7D(-11-35) AGU AAG AUU CAC UUU CAU AAU GCU G 25
SMN2E7D(-14-38) AAA AGU AAG AUU CAC UUU CAU AAU G 25
Sham CAG GAG ACG CCG GGC CUC CU 20
doi:10.1371/journal.pone.0062114.t001
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the shorter PMO(-10-29) when compared to the longer PMO(-10-
34), there was a trend to longer survival. The question that occurs
is what happens on multiple injections; a critical question that has
not been addressed for either the morpholino or MOE chemis-
tries. We have previously re-administered the PMO(-10-29) at
postnatal 28 days after ICV injection at P0 and additional
injection did not further prolong the survival. However we did not
test distribution of the PMO in the CNS of adult animals and this
is critical to the effectiveness of therapy. We suggested that in the
current study the PMO(-10-34) exerts an affect on SMN2 that lasts
slightly longer than a PMO(-10-29). If this is the case then the
difference in use of PMO(-10-29) and PMO(-10-34) may well be
the frequency of reintroduction. Currently we would predict an
approximately a monthly introduction of AO based on the decay
of SMN amounts [21]. Further studies are required to determine
the optimal reintroduction strategy in SMA, a critical parameter in
the successful implementation of antisense oligonucleotides in
SMA.
Materials and Methods
Cell Culture Propagation
A type I SMA fibroblast obtained from Coriell Cell Repositories
was propagated in 10 ml of 10% foetal bovine serum in Dulbecco
minimum eagle media (DMEM) with Glutamine supplemented
with penicillin (10 U/ml) and streptomycin (10 mg/ml). 1.56104
cells were seeded into 24-well and subsequently incubated for 24
hours prior to transfection.
Figure 2. a) Splicing pattern of SMN transcript in type I SMA patient cells transfected with PMOs or unrelated negative control
(Sham PMO) using lipofectin to compare the efficiency of PMOs of different length. b) The lower panel shows the average percentage of
SMN2 exon inclusion as determined by densitometric analysis of RT-PCR gel images.
doi:10.1371/journal.pone.0062114.g002
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Figure 3. a) Splicing pattern of SMN transcript in type I SMA patient cells transfected with a panel of 22-mer PMOs or unrelated
negative control (Sham PMO) using lipofectin. b) The lower panel shows the average percentage of SMN2 exon inclusion as determined by
densitometric analysis of RT-PCR gel images.
doi:10.1371/journal.pone.0062114.g003
Figure 4. A titration study of the three lead PMOs: Splicing pattern of SMN transcript in type I SMA patient cells transfected with
PMOs or unrelated negative control (Sham PMO) using lipofectin.at concentrations indicated. The percentage of SMN2 exon inclusion as
determined by densitometric analysis of RT-PCR gel images is also shown.
doi:10.1371/journal.pone.0062114.g004
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Phosphorodiamidate Morpholino Oligonucleotide and
Primers
Oligonucleotide nomenclature specifies the intronic annealing
coordinates, hence PMO(-10-29) describes a compound annealing
between bases 10 and 29 from the beginning of SMN2 intron 7.
PMOs were manufactured and supplied by Gene-Tools (Philo-
math, USA). The sequences of the PMO investigated are designed
to refine the silencing motif (ISS-N1) previously described [19],
and the list of tested PMO was provided in Table 1. For in vitro
experiment, PMOs were resuspended in normal saline for
fibroblast transfection. The DNA leashes for PMO transfection
and the primers for RT-PCR were synthesized by Geneworks
(Adelaide, Australia). For the ICV injection, PMOs were prepared
in sterile 0.9% sodium chloride, and mixed with Evans Blue (final
concentration 0.04%); three different molar concentrations were
prepared at different concentrations and stored at 220uC.
PMO Transfection
PMOs:DNA leash lipoplex method was used to enhance
transfection efficiency, as previously reported. [30] Briefly, the
initially PMO:leash working solutions were prepared at a final
concentration of 50 mM of both PMO and respective leash at a 1:1
molar ratio. After annealing, this PMO mixture was then utilised
to transfect onto a type I SMA fibroblasts, using lipofectin agent
Figure 5. a) Western blot analysis of SMN and ß-tubulin in type
I SMA patient cells transfected with PMOs or unrelated
negative control (Sham PMO). b) The lower panel shows the fold
change in SMN, normalised against ß-tubulin, as determined by
densitometric analysis. P-values indicates statistical significance in
SMN expression between PMO(-10-34) and sham PMO.
doi:10.1371/journal.pone.0062114.g005
Figure 6. Western blot analysis of SMN in type I SMA patient fibroblasts nucleofected with PMOs or unrelated negative control
(Sham PMO). The fold change in SMN expression, normalised against ß-tubulin is shown.
doi:10.1371/journal.pone.0062114.g006
Figure 7. Western blot analysis of SMN and ß-actin in a) spinal
cord and b) brain of SMA carrier mice (Smn+/2; SMN2+/+; D7+/+)
intracerebroventricularly injected with 6 mM of PMO(-10-34)
or scrambled PMO control. Tissues were collected at 7, 21 and 65
days after PMO(-10-34) injection and at 21 days after scramble PMO
injection.
doi:10.1371/journal.pone.0062114.g007
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(Lifetechnology) at a ratio of 2:1 Lipofectin to PMO mix.
Lipofectin was mixed with DMEM (Invitrogen) to a final volume
of 100 ml. The PMO mix, which had been diluted to 100 ml in
DMEM, was then combined with the Lipofectin/DMEMmixture.
The mixture was then made up to a final volume of 1 ml using
antibiotic-free medium. 500 ml aliquots of this mixture were added
to each well of 24-well plate containing SMA fibroblast and
incubated for 48 hours.
Nucleofection was undertaken using Amaxa 4D kit (Lonza).
Two microliter of stock PMO was added into a cuvette, and
a quarter of a million of SMA fibroblasts were resuspended into
18 ml of pre-warmed transfection solution, and then add to the
cuvette. The mixture of fibroblast solution and PMO was
subsequently nucleofected using Amaxa 4D Machine.
RNA Extraction and RT-PCR
Total RNA was harvested from type I SMA fibroblast using
Trizol (LifeTechnology), according to the manufacturer’s protocol.
One step RT-PCR using Superscript III: ,150 ng of total RNA
was used as a template and incubated for 30 min at 55uC, and at
94uC for 2 min, before 28 rounds of 94uC for 40 sec, 56uC for
1 min and 68uC for 1 min using exon 4F and 8R primers. PCR
products were fractionated on 2% agarose gels in Tris-Acetate-
EDTA buffer and the images captured on a Chemismart-3000 gel
documentation system and analysed with Bio1D software to
quantitate band weight and estimate ratios of SMN-FL and
SMND7. Product identity was confirmed by band purification and
DNA sequencing as necessary.
Table 2. Comparison of mean and median survival time of SMN mice injected with PMO(-10-34) or Scramble.
Doses Mean survival time (day) Median survival time (day) Log Rank test P-value
2 mM 99.5 VS 83.0 110 VS 83 0.543
4 mM 117.2 VS 111.0 110 VS 106 0.700
6 mM 135.3 VS 102.9 126 VS 112 0.097
doi:10.1371/journal.pone.0062114.t002
Figure 8. Survival curve of SMA mice intracerebroventricular injected with different dosage of PMO(-10-34).
doi:10.1371/journal.pone.0062114.g008
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Western Blotting
Protein extracts were prepared according to Cooper et al., 2003,
[31] but with 15% SDS. SDS-PAGE electrophoresis was performed
using NuPAGE Novex 4–12% BIS/Tris gels run at 200V for 55
minutes. Proteins were transferred to Pall Fluorotrans W PVDF
membranes at 30 V for 1 hour at 18uC. For SMN detection in
fibroblasts, MANSMA1 antibody was applied at 1:100 dilution
overnight at 4uC. For SMN detection in Smn mice, human specific
SMNantibody (KHantibody) was applied at 1:20 dilution overnight
at 4uC [32]. Invitrogen Western Breeze kit was used for immuno-
detection. Quantification was performed on a Vilber Lourmat
Chemi-Smart 3000 system using Chemi-Cap software for image
acquisition and Bio-1D software for image analysis. ß-tubulin was
detected by a mouse monoclonal antibody (BD Pharmingen, Cat.
no 556321), as a reference loading protein. ß-actin was detected by
a rabbit monoclonal antibody (Cell Signaling, Cat. no 4970), as
a reference loading protein for mouse tissue.
Generation of SMA Mice and Mouse Genotyping
D7 carrier breeding mice (SMN2+/+; Smn+/2; SMND7+/+)
were crossed to generate three types of offspring varying in the
mouse Smn genotype: Smn +/+, Smn +/2, Smn 2/2 as previously
described. All breeding and subsequent use of animals in this study
were approved by the IACUC of The Ohio State University,
Columbus, Ohio. SMA mouse were genotyped at postnatal day
0 via tail clip, and all genotyping was performed during day 0 as
described previously [11].
Figure 9. Mass of SMA mice intracerebroventricularly injected with PMO(-10-34) at five different doses.
doi:10.1371/journal.pone.0062114.g009
Table 3. Comparison of the mean and median survival time between the mice injected with different dosages of PMO(-10-34) or
PMO(-10-29).
Dosage
Mean survival
time (day) 95% CI
Median survival
time (day) 95% CI
Log-Rank test
P-Value
0.5 mM 49.0 (30.9, 67.01) 37 (28.2, 45.8) ,0.001*
1.0 mM 72.7 (39.3, 106.0) 65 (11.2, 118.8) 0.005*
2 mM 99.5 (29.2, 42.3) 110 (29.6, 190.4) 0.03*
4 mM 117.2 (98.7, 135.7) 106 (101.7, 110.3) 0.001*
6 mM 135.3 (108.7, 162.0) 126 (97.2, 154.8) ,0.001*
*indicate statistical significant.
doi:10.1371/journal.pone.0062114.t003
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ICV injection was performed as previously described [21].
Statistical Analysis
T-test was used to compare the fold changes in SMN expression
between PMO(-10-34) transfected and sham PMO treated
samples. For the survival curve analysis, data are expressed as
means plus standard errors. Kaplan–Meier curves were generated
from the survival data and tested using the Mantel–Cox log-rank
test. All statistical analyses were performed using SPSS, v.16.0.
Supporting Information
Figure S1 Schematic diagram representing PMO bind-
ing coordinates on human SMN2 intron 7.
(PDF)
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